These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 14506197)

  • 21. Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display.
    Salvatore G; Beers R; Margulies I; Kreitman RJ; Pastan I
    Clin Cancer Res; 2002 Apr; 8(4):995-1002. PubMed ID: 11948105
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma.
    Vallera DA; Todhunter DA; Kuroki DW; Shu Y; Sicheneder A; Chen H
    Clin Cancer Res; 2005 May; 11(10):3879-88. PubMed ID: 15897589
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of the expression and gene promoter of CD22 in murine B cells.
    Andersson KB; Draves KE; Magaletti DM; Fujioka S; Holmes KL; Law CL; Clark EA
    Eur J Immunol; 1996 Dec; 26(12):3170-8. PubMed ID: 8977319
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intracellular CD22 rapidly moves to the cell surface in a tyrosine kinase-dependent manner following antigen receptor stimulation.
    Sherbina NV; Linsley PS; Myrdal S; Grosmaire LS; Ledbetter JA; Schieven GL
    J Immunol; 1996 Nov; 157(10):4390-8. PubMed ID: 8906814
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human hematopoietic cell lines: a model system for study of minimal residual disease detection technique in acute leukemia.
    Koníková E; Kusenda J; Babusíková O; Glasová M
    Neoplasma; 1995; 42(5):227-34. PubMed ID: 8552200
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
    Jazirehi AR; Bonavida B
    Oncogene; 2005 Mar; 24(13):2121-43. PubMed ID: 15789036
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of CD22 with the B cell antigen receptor.
    Peaker CJ; Neuberger MS
    Eur J Immunol; 1993 Jun; 23(6):1358-63. PubMed ID: 7684686
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnostic usefulness of aberrant CD22 expression in differentiating neoplastic cells of B-Cell chronic lymphoproliferative disorders from admixed benign B cells in four-color multiparameter flow cytometry.
    Huang J; Fan G; Zhong Y; Gatter K; Braziel R; Gross G; Bakke A
    Am J Clin Pathol; 2005 Jun; 123(6):826-32. PubMed ID: 15899772
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting malignant B-cell lymphoma with a humanized anti-CD22 scFv-angiogenin immunoenzyme.
    Krauss J; Arndt MA; Vu BK; Newton DL; Rybak SM
    Br J Haematol; 2005 Mar; 128(5):602-9. PubMed ID: 15725080
    [TBL] [Abstract][Full Text] [Related]  

  • 30. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
    Wu L; Adams M; Carter T; Chen R; Muller G; Stirling D; Schafer P; Bartlett JB
    Clin Cancer Res; 2008 Jul; 14(14):4650-7. PubMed ID: 18628480
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma.
    Leonard JP; Coleman M; Ketas J; Ashe M; Fiore JM; Furman RR; Niesvizky R; Shore T; Chadburn A; Horne H; Kovacs J; Ding CL; Wegener WA; Horak ID; Goldenberg DM
    J Clin Oncol; 2005 Aug; 23(22):5044-51. PubMed ID: 15955901
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficient killing of CD22+ tumor cells by a humanized diabody-RNase fusion protein.
    Krauss J; Arndt MA; Vu BK; Newton DL; Seeber S; Rybak SM
    Biochem Biophys Res Commun; 2005 Jun; 331(2):595-602. PubMed ID: 15850802
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma.
    Strauss SJ; Morschhauser F; Rech J; Repp R; Solal-Celigny P; Zinzani PL; Engert A; Coiffier B; Hoelzer DF; Wegener WA; Teoh NK; Goldenberg DM; Lister TA
    J Clin Oncol; 2006 Aug; 24(24):3880-6. PubMed ID: 16864854
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Different expression of CD3 and CD22 in leukemic cells according to whether tested in suspension or fixed on slides.
    Rani S; De Oliveira MS; Catovsky D
    Hematol Pathol; 1988; 2(2):73-8. PubMed ID: 2974027
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of CD22 binding to native CD45 and synthetic oligosaccharide.
    Bakker TR; Piperi C; Davies EA; Merwe PA
    Eur J Immunol; 2002 Jul; 32(7):1924-32. PubMed ID: 12115612
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study.
    Steinfeld SD; Tant L; Burmester GR; Teoh NK; Wegener WA; Goldenberg DM; Pradier O
    Arthritis Res Ther; 2006; 8(4):R129. PubMed ID: 16859536
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The same epitope on CD22 of B lymphocytes mediates the adhesion of erythrocytes, T and B lymphocytes, neutrophils, and monocytes.
    Engel P; Nojima Y; Rothstein D; Zhou LJ; Wilson GL; Kehrl JH; Tedder TF
    J Immunol; 1993 Jun; 150(11):4719-32. PubMed ID: 7684411
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls.
    Jacobi AM; Goldenberg DM; Hiepe F; Radbruch A; Burmester GR; Dörner T
    Ann Rheum Dis; 2008 Apr; 67(4):450-7. PubMed ID: 17673490
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of serotherapy target antigens in Waldenstrom's macroglobulinemia: therapeutic applications and considerations.
    Treon SP; Kelliher A; Keele B; Frankel S; Emmanouilides C; Kimby E; Schlossman R; Mitsiades N; Mitsiades C; Preffer F; Anderson KC
    Semin Oncol; 2003 Apr; 30(2):248-52. PubMed ID: 12720146
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma.
    DiJoseph JF; Goad ME; Dougher MM; Boghaert ER; Kunz A; Hamann PR; Damle NK
    Clin Cancer Res; 2004 Dec; 10(24):8620-9. PubMed ID: 15623646
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.